Comparative Pharmacology
Head-to-head clinical analysis: IONTOCAINE versus LIDOCAINE HYDROCHLORIDE 0 2 AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IONTOCAINE versus LIDOCAINE HYDROCHLORIDE 0 2 AND DEXTROSE 5 IN PLASTIC CONTAINER.
IONTOCAINE vs LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iontocaine (lidocaine 2% and epinephrine 0.01%) combines a sodium channel blocker (lidocaine) to inhibit nerve impulse propagation, producing local anesthesia, with epinephrine causing vasoconstriction to reduce systemic absorption and prolong effect.
Lidocaine is a sodium channel blocker that stabilizes neuronal membranes by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby producing local anesthesia. Dextrose 5% provides caloric support.
IONTOCAINE is not a recognized drug. No standard dosing available.
Intravenous administration: Initial dose of 1-1.5 mg/kg (up to 300 mg total) given at a rate not exceeding 50 mg/min. Followed by continuous infusion at 1-4 mg/min (20-50 mcg/kg/min) for arrhythmia management.
None Documented
None Documented
Terminal elimination half-life is 2.5-3.0 hours; prolonged in renal impairment (up to 6-8 hours).
Terminal elimination half-life: 1.5–2 hours (prolonged to 2–3 hours in hepatic impairment; unchanged in renal impairment).
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (15-20%); less than 10% fecal.
Renal excretion of unchanged drug and metabolites: 10% unchanged, 90% as metabolites (primarily 4-hydroxy-2,6-xylidine and glycylxylidide). Less than 1% biliary/fecal.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)